Consistent handling and preparation processes designed to support reliable research protocols
The purported health benefits now appear to be even more far-reaching, with the latest data from a trial called Select, published in 2023, showing that semaglutide can slash the risk of heart attacks and strokes by a fifth in patients with an existing history of cardiovascular disease
Preterm birth: More common, sometimes iatrogenic due to complications
N Engl J Med 381:19952008 Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
allergic reactions (rash, difficulty breathing, facial swelling)
This shift mirrors historical inflection points in other scientific domains, where progress accelerated not through incremental refinement, but through redefinition of the underlying framework